Framingham drug maker to test pre-eclampsia med
rEVO Biologics of Framingham will begin the third testing phase of a drug intended to treat pre-eclampsia in pregnant women.
The trial will assess whether the company’s ATryn prolongs pregnancy in mothers with early onset preeclampsia, consequently reducing the high rates of neonatal mortality and disability caused by the condition, said rEVO, a subsidiary of Europe-based LFB SA. Preeclampsia is a condition that affects the placenta and may lead to decreased blood flow, nutrients and oxygen from mother to fetus, placing the baby at risk for prematurity and abnormal fetal growth, according to a rEVO statement.
The first patient was enrolled by a medical team at the University of Alabama, Birmingham, according to the company.
“With our trial of ATryn in early onset preeclampsia now underway, we look forward to having clinical investigators across the country join us in assessing ATryn as a treatment option for a subset of women with early onset preeclampsia who are faced with delivering a severely premature baby,” said Yann Echelard, president and CEO of rEVO Biologics.
The Preeclampsia Foundation estimates the annual cost of treating preeclampsia in the United States at more than $7 billion.
WBJ Web Partners
Most Recent
Most Recent
0 Comments